Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab
Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Salloway S, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Andersen S, Holdridge K, Mintun M, Sims J, Yaari R, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.041129.Peer-Reviewed Original ResearchDisease prevention trialsPrevention trialsAlzheimer's disease prevention trialsDifferent antigenic targetsSignificant neuronal lossKey secondary outcomesParallel-group trialAD prevention trialsAdaptive platform trialFuture clinical trialsBeta monoclonal antibodyTiming of treatmentSymptomatic ADLast patientSecondary outcomesSymptom onsetNeuronal lossTop-line resultsTreatment trialsTau-PETAntigenic targetsBrain damageClinical trialsPlatform trialsAD hypothesesGantenerumab in‐depth outcomes
Salloway S, Bateman R, Aschenbrenner A, Benzinger T, Clifford D, Coalier K, Cruchaga C, Fagan A, Farlow M, Goate A, Gordon B, Hassenstab J, Jack C, Koeppe R, McDade E, Mills S, Morris J, Santacruz A, Snyder P, Wang G, Xiong C, Snider B, Mummery C, Surti G, Hannequin D, Wallon D, Berman S, Lah J, Jiménez‐Velazquez I, Roberson E, van Dyck C, Honig L, Sanchez‐Valle R, Brooks W, Gauthier S, Masters C, Galasko D, Brosch J, Hsiung G, Jayadev S, Formaglio M, Masellis M, Clarnette R, Pariente J, Dubois B, Pasquier F, Baudler M, Delmar P, Doody R, Fontoura P, Kerchner G, Team D. Gantenerumab in‐depth outcomes. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.038049.Peer-Reviewed Original ResearchSporadic Alzheimer's diseaseAlzheimer's diseaseCognitive endpointsCDR-SBAmyloid PETBiomarker outcomesMutation carriersSecondary clinical outcomesSecondary efficacy endpointsAutosomal dominant Alzheimer's diseaseClinical trial programClinical Alzheimer's diseaseBeta monoclonal antibodySymptomatic Alzheimer's diseaseAnti-amyloid antibodiesCognitive compositeSymptomatic mutation carriersEfficacy endpointPlacebo groupPrimary outcomeClinical outcomesInitial doseFluid biomarkersTau-PETAmyloid reduction